Multivalent COVID vaccines to help address emergence of variants: CMC and Clinical implications

Combined Manufacturing and Clinical Development SWAT Team | Wednesday April 14, 2021
Meeting Norms and Recording Disclaimer

• Throughout the workshop, please ask questions in the “Q&A” function. If you see that your question is already asked, you can “like” the question in the “Q&A” function.

• This workshop will be recorded. Please be mindful of the diverse audience attending the meeting when participating in open discussions.
# Agenda

## Introduction
- **10 min** Introductions, meeting overview and rules
  - Ajoy Chakrabarti, BMGF
- **15 min** Current thinking: regulatory expectations for variant vaccines
  - Dean Smith & Catherine Njue, Health Canada

## Manufacturing case studies
- **20min** Multi-filo vaccine design based on an MVA platform
  - Hubertus Hochrein, Bavarian Nordic
- **20 min** Challenges of developing a multivalent vaccine for the global market: Gardasil®9
  - Paula Annunziato & Dicky Abraham, Merck
- **20 min** Introducing new flu strain and challenges with multivalent vaccines
  - Beverly Taylor, Seqirus
- **5 min** Break

## Clinical case studies
- **10 min** Introduction
  - Jakob Cramer, CEPI
- **10 min** Immunological perspectives
  - Arnaud Didierlaurent, University of Geneva
- **15 min** Takeda bivalent norovirus vaccine
  - Jim Sherwood, Takeda
- **15 min** Sanofi TIV to QIV influenza vaccine
  - Kevin Yin and Sandrine Samson, Sanofi
- **20 min** Moderna COVID-19 vaccines
  - Darin Edwards, Brett Leav, and Carla Vinals, Moderna

## Concluding Remarks and Wrap-up
- **10 min** WHO support to regulatory preparedness
  - David Wood, WHO
- **10 min** Meeting close and discussion
  - Jakob Cramer, CEPI
Introduction

• Addressing the variants will impact development activities related to COVID-19 vaccines for the foreseeable future.

• There have been multiple workshops addressing how to introduce a modified or new vaccine to address variants. Today we are focused on **multivalent** vaccines (containing for example an antigen against the prototype strain as well as an antigen directed against a variant) and the lessons learned by others when developing such multivalent vaccines.

• Joint Workshop between the CMC and Clinical SWAT teams has several potential benefits:
  • Highlight the interrelated nature of Clinical and CMC efforts
  • Cross-over learning opportunity to understand how issues from one area impacts the other

• Three major **CMC Themes** for vaccine candidates that cover multiple COVID-19 variants:
  • Impact on potency assays and setting release specifications
  • Impact on formulation and stability
  • Difference between multiple DS that are blended together versus multiple antigens in a single DS

• Three major **Clinical Themes**:
  • Risk of immunological interference. Demonstrate the immunological response to the first antigen is undeterred by the addition of the additional type(s).
  • How to benchmark the response to the new antigen against the response of the prototype vaccine antigen.
  • Safety: the impact of potentially increased antigen amount versus the risk of reduced-dosing failing non-inferiority.
Current regulatory thinking on multivalent vaccines: Nimble regulation during a pandemic

COVAX Workshop:
Multivalent COVID-19 vaccines to help address emergence of variants:
CMC and Clinical implications
April 14, 2021

Biologic and Radiopharmaceutical Drugs Directorate
Health Canada
Dean Smith & Catherine Njue
Context

• Several prototype COVID-19 products with moderate to high vaccine efficacy have been developed, evaluated in large placebo controlled randomised clinical trials (RCT), authorised and are being deployed in record time

• These prototype vaccines are based on monovalent full-length SARS-CoV-2 original strain Spike(S) protein, native or pre-fusion stabilized

• While longer term characterization of multivalent COVID-19 based vaccines may be prudent, for the rapid development of VOC adapted vaccines, developers should be aware of the potential for additional CMC and clinical challenges with multivalent vaccines against S and other antigens, when broadly neutralizing monovalent adapted VOC S designs may be possible
Outline: CMC Considerations

- **CMC Development**
  - General considerations
  - Single antigen DS requiring blending
  - Multiple antigen in single DS
  - VOC Adapted antigen for authorised and new vaccines

- **Setting specifications**
  - General considerations
  - Dose ranging studies to support specifications
  - Potential complexities with multivalent vaccines
CMC Development

General considerations:

• CMC characterization and QC for vaccine antigens in a multivalent vaccine same as that for monovalent, with the additional consideration of antigen interference in the QC assays (e.g., ID, potency and potentially other CQA).

• Single antigen DS requiring blending:
  – Permits more direct control specific antigen additions to DP
  – Simplifies the characterization of antigen interference in QC assays, as well as the characterization of potential antigen competition in pre-clinical and clinical studies
  – Requires multiple production runs for DP, and antigen assay specificity in the DP is still required at release and during stability testing
CMC Development

• **Multiple antigens in a single DS:**
  - Control of specific antigen content in a single expression cassette more complex and less flexible
  - Single production run to produce DP, but same assay specificity requirements at DS and DP
  - Will still require monovalent antigen production during development to characterize antigen QC assays and potentially antigen completion in pre-clinical and clinical studies

• **VOC Adapted antigen design:**
  - VOC adapted antigen can be consideration for authorized vaccines, as well as products still in development for both mono and multivalent vaccines
  - **Note:** A demonstration of the added CMC (or clinical) value for all vaccine components, including additional antigens, is generally required
Setting specifications with multivalent vaccines

- Generally, specifications must be based on characteristics of vaccine lots demonstrated to be safe and effective in clinical studies or through clinical experience (i.e., clinically related/patient-centric specifications).

- Dose ranging studies characterizing NAb and CMI can be as important for setting specifications as there are to determine the target clinical dose in Phase III. Can be essential to support a product through authorization, if clinical lot potency is challenging to maintain though commercial scale up. Also “protects” specifications post-authorization.

- Potential complexity with release/end of shelf-life specifications with multivalent vaccines and differing rates of potency decline between multiple antigens.
Outline: Clinical Considerations

- Clinical Development
- Need for Dose Finding Studies
- Study Designs to Assess Immune Response
- Vaccines Still Under Development
Clinical Development

• Clinical development program will vary for proposed multivalent vaccines and a distinction should be made between:
  – Multivalent vaccines based on an authorized platform with clear demonstration of efficacy based on a clinical disease endpoint versus
  – Multivalent vaccines based on platforms which are not yet authorized
Dose Finding Studies

• For COVID-19 vaccines which have already been authorised:
  – the generation of a bi- or multivalent vaccine will likely necessitate additional immunogenicity studies to define the appropriate dose for each sequence
  – Hence, properly designed dose finding studies to determine the optimal dose for each sequence should be conducted
Dose Finding Studies

• Such studies will not only provide important dose-finding information but also safety information

• The design of such studies should be discussed early with regulators
Assessing Immune Response

• Once the optimal dose for each sequence has been determined:
  – Studies will also be needed to investigate whether the addition of a second (or subsequent) sequence(s) does not result in an inferior immune response to vaccines with a single sequence
  – The reactogenicity of the multivalent vaccine relative to the single sequence vaccine should also be evaluated
Assessing Immune Response

• This will necessitate the need for properly designed non-inferiority studies

• The study population, endpoints and non-inferiority margins selected should be justified

• The number of subjects enrolled in the study should be clearly justified based on the design and objectives of the study
Vaccines Still Under Development

• For multivalent vaccines based on platforms which are not yet authorized:
  – Clinical development plans will depend on the stage of development including available data on immunogenicity, safety and efficacy
  – It is best that such plans are discussed early with regulatory agencies
Thank-You!

Questions?
Multi-filo vaccine design based on an MVA platform

Hubertus Hochrein, PhD
VP Research, Bavarian Nordic
Filovirus

non segmented/ negative strand RNA
19kb, 7 genes, overlapping genes
• Infections cause severe form of hemorrhagic fever
• Lethality in humans ranges from 23 to 90%
• High level of person-to-person transmission

• Ebola virus (EBOV):
  • 5 strains
  • 3 involved in morbidity and death of humans:
    • Zaire ebolavirus; Sudan ebolavirus; Bundibugyo ebolavirus
• Marburg virus (MARV):
  • Several strains
Ebola Virus Outbreaks by Species and Size, Since 1976

Marburg HF Outbreak Distribution Map

https://www.cdc.gov/vhf/ebola/history/distribution-map.html

https://www.cdc.gov/vhf/marburg/outbreaks/distribution-map.html
Structure and Genetic Organization of filoviruses

Fields ed.: Virology
Poxviruses as base for multivalent vaccines

Antigenic Complexity

Low

High

Wide Variety of Target Diseases

Recombinant Poxviruses

Simple

Complex

Target Multiple Antigens for a Single Disease

Customized Immunogenicity

Widely Applicable Technology for Infectious Disease and Cancer Immunotherapy

MVA

FPV

Poxviruses Vectors

Antigens

Promoters

Co-Stimulatory Molecules

24
MVA-BN®-Filo

- Designed to protect against Marburg, Ebola Zaire and Sudan, as well as smallpox
- In addition to the major protective antigen GP of all Filoviruses, MVA-BN® multivalent Filo encodes for conserved nucleoprotein (NP), known to induce good T cell responses

<table>
<thead>
<tr>
<th>Strain</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP-SEBOV</td>
<td>Glycoprotein of Sudan Ebolavirus (Boniface strain)</td>
</tr>
<tr>
<td>GP-ZEBOV</td>
<td>Glycoprotein of Zaire Ebolavirus (Mayinga strain)</td>
</tr>
<tr>
<td>GP-MARV-Musoke</td>
<td>Glycoprotein of Musoke Marburgvirus</td>
</tr>
<tr>
<td>NP-CdI-EBOV</td>
<td>Nucleoprotein of Ivory Coast Ebolavirus</td>
</tr>
</tbody>
</table>
Efficacy of MVA-BN® multivalent Filo against Marburg in NHP

Study 1

<table>
<thead>
<tr>
<th>Group ID</th>
<th>N</th>
<th>Test/Reference Item Administration</th>
<th>Challenge Day 42</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>TBS control</td>
<td>Days 0 and 28</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>MVA-BN-multifilo</td>
<td>Marburg Musoke</td>
</tr>
</tbody>
</table>

- Immunogenic in mice and NHP
- Complete protection from death and clinical symptoms in NHP
MVA-BN® Filo and FPV-Filo

Heterologous Vaccination of NHP with Fowlpox (FPV-filo)/MVA-BN-filo and Ebola-Zaire challenge
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Stanley et al. Nat Med 2014 (doi:10.1038/nm.3702)

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. .... Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.

Ten months after the prime, macaques were administered a lethal dose (1,000 PFU) of EBOV. Graph indicates percentage of surviving animals.
The combination of Adenovirus and MVA induces strong adaptive immune responses

- The combination of Ad26 + MVA-BN-filo induces full protective immune responses in NHPs challenged with Ebola
- Ad26 or ChAd3 + MVA-BN-filo induce long lasting high antibodies and T cell responses to Ebola proteins in clinical trials in the USA, Europe and Africa

Tapia et al, Lancet Infect Dis 2015

Milligan et al. JAMA 2016
ChAd3 +MVA-BN boost enhances human CD4 and CD8 T-cell quality (Ebola)

Tapia et al. Lancet Inf Dis 2015
Summary of MVA-BN as a multivalent vector

- MVA-BN-filo demonstrates that MVA could be the basis for multivalent vaccines.

- MVA-BN-filo induced immune responses to the incorporated transgenes covering the lethal filovirus family.

- Synergy with another single vector multivalent vaccine (FPV-multifilo) in protecting against EBOV challenge in NHP.

- MVA-BN-filo demonstrated strong synergy with monovalent adenoviruses in protecting NHP against EBOV challenge.

- In combination with monovalent adenoviruses MVA-BN-filo synergistically induced strong (antibodies and T cells) and durable immune responses in various clinical trials.
CHALLENGES OF DEVELOPING A MULTIVALENT VACCINE FOR THE GLOBAL MARKET: GARDASIL®9

14-April-2021
Dicky Abraham, Distinguished Scientist, Global Vaccines, Merck Manufacturing Division
Paula Annunziato, Vice President, Vaccines Global Clinical Development
Clinical Aspects
GARDASIL®9

Composition of GARDASIL 9

**Impact of Adding 5 HPV Types**

<table>
<thead>
<tr>
<th>Type of Lesion</th>
<th>GARDASIL 9 Types Contribution</th>
<th>GARDASIL® Types Contribution</th>
<th>Contribution of HPV Types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer*</td>
<td>90%</td>
<td>70%</td>
<td>20%</td>
</tr>
<tr>
<td>CIN2/3**</td>
<td>80%</td>
<td>50%</td>
<td>30%</td>
</tr>
<tr>
<td>CIN1**</td>
<td>50-60%</td>
<td>30-35%</td>
<td>20-25%</td>
</tr>
</tbody>
</table>

* Based on de Sanjose et al. 2010 and Serrano et al. 2012
** Based on Joura et al. 2014

Overview of Clinical Program

P001, phase 3 safety and efficacy study (~14,000 subjects)
- Clinical efficacy for new types and immunobridging to original types in 16-26-year-old women
- Active comparator GARDASIL®
- Immunobridging from GARDASIL to GARDASIL 9
- All primary and secondary hypotheses were met

Ten phase 3 safety and immunogenicity studies (>12,500 subjects)
- Immunobridging from women 16-26 years of age(3 doses) to girls and boys 9-15 years of age (2- or 3-doses), men 16-26 years of age (3 doses) and women 27-45 years of age (3 doses)
- Immunobridging from GARDASIL to GARDASIL 9 (girls 9-15 years of age, men 16-26 years of age)
- Concomitant use (Menactra, Adacel, Repevax)
- Prior recipients of GARDASIL®
- Manufacturing lot consistency
- All primary and secondary hypotheses were met

### Three Decades of Quadrivalent HPV (qHPV) and 9-valent HPV (9vHPV) Vaccine Development

<table>
<thead>
<tr>
<th>Year</th>
<th>qHPV Vaccine</th>
<th>9vHPV Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>(proof of concept)</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>Monovalent vaccines</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>qHPV vaccine (girls, boys, young women)</td>
<td>9vHPV vaccine (girls, boys, young women/men)</td>
</tr>
<tr>
<td>2000</td>
<td>qHPV vaccine (adult women, young men)</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>qHPV vaccine (2-dose: girls; investigator-initiated)</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>qHPV vaccine (China, India, Japan registration)</td>
<td>9vHPV vaccine (China, Japan, Vietnam registration)</td>
</tr>
<tr>
<td>2003</td>
<td>2nd generation vaccine (Phase 2 studies)</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>9vHPV vaccine (girls, boys, young women/men)</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>9vHPV vaccine (2-dose: girls and boys)</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>9vHPV vaccine (adult women)</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>9vHPV vaccine (oral persistent infection; adult men)</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2024</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2026</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2027</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2028</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2029</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Green:** Long-term follow-up
- **Orange:** Licensure
- **Yellow:** 2 doses 6 to 12 months apart
- **Red:** 2 doses 1 to 5 years apart

**Key Events:**
- 1998: Development of qHPV vaccine for girls, boys, and young women.
- 1999: Development of qHPV vaccine for adult women and young men.
- 2000: Development of qHPV vaccine (2-dose) for girls; investigator-initiated trials.
- 2001: Registration of qHPV vaccine in China, India, and Japan.
- 2002: Development of 2nd generation vaccine (Phase 2 studies).
- 2003: Development of 9vHPV vaccine for girls, boys, and young women/men.
- 2004: Development of 9vHPV vaccine (2-dose) for girls and boys.
- 2006: Registration of 9vHPV vaccine in China, Japan, and Vietnam.
- 2007: Development of 9vHPV vaccine (oral persistent infection; adult men).
- 2008: Licensure of qHPV vaccine.
- 2009: Licensure of 9vHPV vaccine.
The Journey Continues - Regulatory and Recommendation Updates

Gardasil approved in >130 countries; Gardasil 9 approved in >80 countries

- Examples of recent regulatory approvals:
  - Gardasil 9 approval for females 16-26 years in China (2018)
  - Gardasil 9 oropharyngeal and other head and neck cancer indication in US (2020)
  - Silgard 9 approval in Japan (2020)
  - Gardasil female 9-19 years indication in China (2020)
  - Gardasil male ≥ 9 years indication in Japan (2020)

>80 countries with HPV vaccine in National Immunization Program

- Examples of recent recommendations
  - Gender neutral vaccination in EU countries (2018-2019)
  - Mid-adults in US (2019)

Increased interest in HPV vaccination

- HPV disease elimination has been a goal for WHO and certain countries since 2018
- Supply constraint due to sharp increase in demand for Gardasil/Gardasil 9 since 2018
CMC Aspects
GARDASIL®9 Based on Human Papillomavirus (HPV) Virus-Like Particle (VLP)

- L1 protein (55 or 57 kDa)
- L1 Capsomer (Pentamer) (~280 kDa)
- 5 × L1
- ~ 3 nm
- ~ 10 nm
- ~ 60 nm

- Virus-Like Particle (~20,000 kDa)
- ~72 × L1 Capsomer

- Vaccine based on HPV major capsid protein, L1, self-assembled into virus-like particles (VLPs)
- Complex structure, but well characterized

(Crystal structure coordinates courtesy of Prof. S. C. Harrison, Harvard University)
Gardasil®9 Manufacturing Process

**Opportunity:**
- GARDASIL®9 developed based on Platform Process
- Monovalent Drug Substance: Ability to accommodate clinical development needs
- Optimization of the production, recovery and purification of the antigen for each type

**Challenges:**
- Drug Product requires 9 distinct Drug Substance inputs
- Difference in scale of process for Drug Substance: Fermentation and Purification and Drug Product
- Inherent complexity of Manufacturing
  - Raw Material Variability
  - Type specific challenges
  - Yield variability
GARDASIL®9 Amenable to Characterization: Robust Control Strategy Achievable

<table>
<thead>
<tr>
<th>Physicochemical Properties</th>
<th>Biological Activity Identity</th>
<th>Purity</th>
<th>Impurities</th>
<th>Contaminants</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Structure</td>
<td>Antigenicity <em>(DS/DP)</em></td>
<td>• Purity (SDS-PAGE) <em>(DS)</em></td>
<td>Host-Cell</td>
<td>• Sterility</td>
<td>• Protein concentration <em>(DS)</em></td>
</tr>
<tr>
<td>Secondary Structure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tertiary - Quaternary</td>
<td><em>In Vitro Relative Potency</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structure</td>
<td>(sandwich ELISA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Solution Antigenicity</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(competitive ELISA – IC50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Epitope Mapping</em> (SPR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Epitope-specific antigenicity</em> (SPR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>In Vivo Potency</em> (mouse ED50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other <em>(DP)</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Aluminum</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>PS-80</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>pH</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Completeness of adsorption</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Release and Stability Indicating


Potency Assay and Implementation

*In Vitro Relative Potency Assay*
- ELISA technology
- Correlates with human immunogenicity and mouse potency
- IVRP measures specific antigenicity and is used for product release

**Implementation**
- Relative potency format
- Reference lot = clinical lot
- Potency of first reference lot defined as its nominal protein dose values, and expressed in Units/ml
- Future reference lots calibrated against frozen standards
Initial Release and Stability Specification

• Clinical performance known for pivotal lots
• Process/analytical capability used to set final specs
• Assurance that commercial lots not less potent
• Issue: Limited number of final container lots and Limited stability data
• Solution: Propagation of error model
Manufacturing Complexity: Supply Chain

“Simple” supply chain with a monovalent product that is filled into 2 finished good images: vials and syringes.

QC=quality control – extensive quality control testing is required throughout the process and may vary by market.
The successful expansion of Gardasil® HPV type coverage to Gardasil®9 leveraged:

- A platform manufacturing process that enables manufacturing of multiple serotype with the same equipment train
- An integrated control strategy that relies on process and analytical control to ensure consistency and quality
- A flexible supply chain to meet changing demand
- A life cycle management approach to respond reactively and proactively to changes
Acknowledgement

Alain Luxembourg
Anita Shaw
David L. Wohlpert
Patricia M. Kotulka
Michael Thien
Thomas Potgieter
Seasonal Influenza overview and challenges

BEVERLY TAYLOR
14 April 2021
Introduction

• To remain effective, the composition of seasonal influenza vaccines must be reviewed and updated for each season to include the HA antigens expressed by the most current circulating influenza wild-type viruses.

• The process to achieve this is lengthy and complex and requires extensive and ongoing collaboration between all stakeholders including influenza manufacturers, WHO, vaccine regulators, and global public health laboratories.

• The process begins with a review of recent global surveillance data the outputs which is used to inform the vaccine virus recommendations made by WHO.

• The vaccine virus recommendations which are provided in February for the Northern Hemisphere (NH) and in September for the Southern Hemisphere (SH) seasons, provide a guide to national public health authorities and vaccine manufacturers for the development and production of multivalent influenza vaccines for the upcoming influenza season.

• It is the responsibility of each national regulatory authority to approve the composition and formulation of the vaccines used in that country.
Seasonal Influenza Overview and Challenges

• Overview of WHO Global Influenza Surveillance and Response System (GISRS)
• Ongoing surveillance and tracking of seasonal candidate vaccine viruses (CVVs)
• Nagoya Protocol/National access and benefit sharing (ABS) legislation
• Timelines for seasonal influenza manufacturing
• Annual regulatory submissions to update product licenses
• Summary of challenges
Overview of WHO Global Influenza Surveillance and Response System (GISRS)

Clinical swabs; virus isolation; preliminary analysis
155 NATIONAL INFLUENZA CENTERS

Virus isolates
Detailed antigenic & genetic analysis
6 WHO COLLABORATING CENTERS

Surveillance data
Review data & recommend vaccine strains
WHO

Recommendation
Review data & decide strains for licensing
LOCAL REGULATOR

Testing
Produce potency testing reagents
4 WHO Essential Regulatory Labs (ERL’s)

Reagents
Confirmatory testing
REGULATORY LABS
National Influenza Centres (NICs)

• NICs are national institutions designated by national Ministries of Health and recognized by WHO
• WHO co-ordinates a surveillance network of 155 laboratories in 125 countries
• Collect virus specimens in their country and perform preliminary analysis to identify and track changing strains as they circulate
• Ship representative clinical specimens and isolated viruses to WHO CCs for further analysis.
WHO Collaborating Centres (CC’s)

• The NIC’s forward representative influenza samples to one of six WHO CC’s who carry out advanced antigenic and genetic analysis

• St. Judes Hospital concentrates on influenza viruses with pandemic potential

• The CC’s collate surveillance information twice per year for WHO strain recommendation

• Provide candidate vaccine viruses (CVVs) to reassortant labs and manufacturers

• Screen viruses for anti-viral resistance
There are four Essential Regulatory Laboratories (ERLs) within GISRS who are responsible for potency assay reagent preparation and calibration:

- NIBSC, UK
- CBER, US
- NIID, Japan
- TGA, Australia
Generation of Virus Seeds by Reassortant Labs

- Reassortant labs prepare high yield reassortant viruses for inactivated influenza vaccine manufacturing.

- There are 6 reassortant laboratories:
  - New York Medical College (NYMC), US
  - NIBSC, UK
  - Seqirus, Australia
  - CBER, US
  - CNIC, China
  - Sanofi, US

- High yield reassortant viruses are made available to all manufacturers

Note: Reassortant labs are not part of the GISRS but interact closely with it.
Ongoing Surveillance Monitoring and tracking of available CVVs

• Regular reviews of surveillance websites such as WHO Fluupdate, CDC Fluview, ECDC Flu news etc.

• Surveillance updates provided at bi-annual NIBSC meetings (Jan and July) and BIO/FDA meeting (Dec) as well as through summaries of internal WHO TCs leading up to strain recommendation

• Tracking surveillance and availability of CVVs for manufacturing through bi-weekly, WHO chaired Technical TCs and real-time spreadsheet of viruses of interest, stage of preparation of CVV’s and availability to manufacturers.

• Year round activity as strain recommendations are changed twice each year (northern hemisphere and southern hemisphere seasons)
Development of CVVs representative of circulating strains

• Receive CVVs of interest to develop high growth reassortant viruses or temperature sensitive viruses to be used in manufacturing.

• Aim is to cover as many of the circulating virus clades and sub-clades as possible prior to strain recommendation.

• The phylogenetic trees of the viruses becoming more and more complex as they are now based on genetic sequences providing much more detail on differences between viruses.

• Difficult to determine which genetic sequence differences result in antigenic changes:
  • Not clear a strain change is required
  • Not clear which viruses are antigenically similar (“like-strains”)

• Manufacturers evaluation of CVVs for suitability in manufacturing process and yield

• Production of Master and Working Seeds
Nagoya Protocol*/ ABS Legislation

• An increasing number of countries have Nagoya Protocol (NP) or National Access and Benefit (ABS) Legislation in place

• Inclusion of pathogens, including influenza, under national ABS legislation is already causing delays and disruptions.

• ABS legislation continues to impact sharing of influenza Genetic Resources (GRs) and, has been/is being amended in a number of countries to include DSI/GSD

• Bilateral negotiation of access and benefit-sharing contracts, including prior informed consent (PIC) and mutually agreed terms (MAT), are lengthy and block any possibility of quickly responding to public health emergencies.

• Pathogens know no borders, global alignment on ABS is essential for responses to global health threats.

• Legal certainty regarding the status of pathogen sharing under ABS legislation is essential.

*Convention on Biological Diversity (Montreal, CAN) signed 29Oct’10, came in to force 12Oct’14, describes Access & Benefit Sharing (ABS) of GRs and traditional knowledge that is accessed for potential research/use and ensures that users and providers agree on fair and equitable sharing of benefits arising from their use

DSI, Digital Sequence Information; GSD, Genetic Sequence Data
Current Situation

• Influenza vaccine virus recommendations are dynamic, with several candidate vaccine viruses (CVVs) being considered for each season

• Most NICs continue to supply influenza viruses under the agreed Terms of Reference as part of GISRS, however there is a lack of legal clarity if the viruses can be used for vaccine manufacturing and research

• It is neither feasible nor efficient to start bilateral negotiations with all CVV provider countries prior to confirmation of recommended viruses. Once the vaccine recommendation is made, there is very little time for manufacturers to conclude bilateral negotiations in time for manufacturing campaign

• NP and ABS legislation differs in each country, is often only available in the local language which poses challenges with interpretation of requirements

• It is not always clear which viruses may be considered as “like” viruses to the recommended virus and could be used as an alternative in manufacturing.

• Several cases of delays in influenza virus sharing due to implementation of the NP/ABS legislation have been already been experienced.
Examples of Impact of Nagoya Protocol/ National ABS Legislation

Since September 2018, over 30 influenza viruses which had been shared with WHO CCs have been impacted by national NP/ABS legislation incurring delays from 3 weeks and up to 5 months before legal clarity has been obtained. In several cases this has resulted in the viruses being available too late for the upcoming influenza season. For some of the more recent viruses legal clarity is still outstanding.

- On 26 Feb 2021, WHO selected a H3N2 influenza strain from Cambodia as a reference strains for use in the NH 2021/22 influenza season. Manufacturers checks indicated that Cambodia had not yet enacted ABS legislation and assumed that use of the Cambodia strain was not being impeded by any potential ABS obligations.

- Days later manufacturers discovered that WHO had contacted Cambodia for clarification and had only received permission for the virus to be used for “non-commercial purposes”. WHO then held discussions with Cambodia to ensure that “commercial use” of the virus was possible and to try to have the benefits accrued by Cambodia through being part of GISRS recognised and accepted.

- This impacted
  - Timing of decisions on which virus to use by manufactures
  - Whether critical reagents would be prepared and made available to manufacturers
  - Possibility that the virus could not be used even though it had been listed on the WHO website for a month
  - Possibility of manufactured batches being discarded
  - “Commercial use” approved but written confirmation that no monetary benefits still outstanding
Seasonal Influenza Vaccine Manufacturing Timeline for NH Supply

- Very tight timelines for manufacturing
- 6 months to first dose, 8 months to last dose
Annual Updates to Product Licenses

- Licensed influenza vaccine manufacturers must submit a supplement to their product license for review for each season and obtain regulatory approval before the updated version of the influenza vaccine containing new virus antigens can be distributed.

- The supplements for live attenuated, inactivated and recombinant protein seasonal influenza vaccines do not require additional clinical data specific for the new strain prior to approval of the new strain to verify adequate attenuation.

- Supplements vary by region/country and include:
  - Virus Manufacturing Seed - derivation and seed lot release certificate
  - Potency reagents – reagent qualification and potency assay validation
  - Drug substance – process qualification (e.g. inactivation kinetics), monobulk release and stability data
  - Drug product – multivalent product release and stability data

- Workload increases with the number of strain changes
**Vaccine Mismatch**

• For some influenza seasons the antigenic drift of the viruses, particularly H3N2s results in a mismatch between the circulating strains and the strains included in the vaccine (e.g. NH 2014/2015 season when a new H3N2 emerged quickly after the strain recommendation)

• Several years ago discussions facilitated by HHS BARDA looked at how this could be addressed including delayed strain recommendation and development of new manufacturing platform technologies

• Recognised that new technologies could allow faster response in manufacturing, but also need to consider time taken for product characterisation, updating licenses, approvals from regulatory agencies and product testing and release.

• Challenges:
  - Need to consider impact of later strain recommendation on vaccination campaigns in all countries/regions
  - Extremely challenging to change a strain in a multivalent vaccine mid-campaign-potential for product write-offs
  - See different predominant viruses in different regions for some seasons
  - Preference for one vaccine per season with possibility for additional monovalent boost based on severity/risk
  - Concern that delays could impact preparations for the following season
  - Public information campaigns would be required to support later vaccine availability to avoid decrease in vaccination rates
Summary of Seasonal Influenza Challenges

• Requires year round surveillance monitoring
• Increasing complexity of virus clades and sub-clades results in more CVVs to consider
• NP/ABS legislation is increasingly a barrier to the access and use of CVVs
• Manufacturing timelines are extremely tight and any delays will impact vaccine supply
• Annual update of licenses is labour and time intensive
• Risk of vaccine mismatch due to ever evolving viruses
• Not even touched on influenza viruses with pandemic potential

Always on the front line and never a dull moment!
Thank You!
Break
Multivalent COVID-19 Vaccines

Clinical Case Studies

Jakob Cramer, MD
Head of Clinical Development
CEPI
14th April 2021
COVID-19 Vaccines Development and VOCs

Vaccine development programmes:

Wave 1
- Pfizer/BNT
- Moderna
- Gamaleya
- AstraZeneca
- J&J
- Sinovac
- Cansino

Wave 1a
- 'X'

Wave 2
- 'Y'

50-70%

WHO strain change ???

Proportion of seropositives, illustrative (natural infection or vaccination)

Global frequencies (coloured by Nextstrain Clade*)

*) Nextstrain clades:
- 19A – original strain
- 20H – includes B.1.351 lineage
- 20I – includes B.1.1.7
- 20J – includes P1 lineages

Vaccine development programmes:

- Monovalent, original strain
  - 2 doses for priming
- Monovalent, adapted to variant strain
  - Single dose for booster / 2 doses for priming?
- Bivalent, original and variant strain (??)
  - Single dose for booster / 2 doses for priming?
Sabin-based Inactivated Poliomyelitis Vaccine (sIPV)

- 3 serotypes: serotypes 2 and 3 eradicated (conventional VE trials impossible)
- 2 vaccines: IPV (injectable, wild-type Salk strains) and OPV (oral, attenuated Sabin strains)
  \(\rightarrow\) sIPV: immune response non-inferior to conventional (Salk-based) IPV
- Infant vaccine: immunizations given @ 6-10-14 weeks in many countries (alternative: 2-3-4 or 2-4-6 months)
  \(\rightarrow\) high proportion of seropositive infants @ baseline (maternal antibodies)
- Established CoP (for Salk-based IPV): nAb titre \(\geq 1:8\)
  \(\rightarrow\) multiple immunogenicity read-outs 28 days after primary immunisation:
    - Geometric mean titre, GMT
    - Seropositivity rate, SPR (=any positive titre)
    - Seroconversion rate, SCR, defined as
      - seronegatives: positive titre \(\geq 8\)
      - seropositive: 4-fold titre increase (accounting for half-life of maternal Abs)
sIPV compared to IPV: Immunologic non-Inferiority

- The primary study objectives should be based on the demonstration of the non-inferiority of the seroconversion rates achieved with the candidate IPV versus the comparator vaccine.
- The primary study analysis should be based on SCRs against both Sabin and wild-type Salk strains.
- The predefined clinical margins of non-inferiority should be justified.

[WHO, TRS No. 993, Annex 3, 2015]

<table>
<thead>
<tr>
<th>Assay strain</th>
<th>Serotype</th>
<th>Serostatus</th>
<th>GMT</th>
<th>SPR</th>
<th>SCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabin</td>
<td>1</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salk</td>
<td>1</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Seronegative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seropositive</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

36 separate strata: In a dose-finding trial with 3 dose levels this would add 3 additional strata.
sIPV: Challenges

• Non-inferiority: sample size specific for immunologic parameter
  ➢ Seropositivity rate likely higher as compared to seroconversion rate (x-fold increase may be difficult in subjects with high baseline titres)

• 2 separate NI assessments: based on Sabin and Salk assays for each of 3 virus serotypes.

• Immune response to homologous assay will likely be superior to heterologous assay
  ➢ Sabin assay: Sabin-IPV → Salk-IPV
  ➢ Salk assay: Salk-IPV → Sabin IPV

• Serotype-specific differences in the immune response → imbalanced antigen concentrations in the vaccine

• Very young age of trial participants: maternal antibodies from OPV- (Sabin-) vaccinated mothers selectively impact immune response to Sabin-IPV?

[WHO, TRS No. 993, Annex 3, 2015; Cramer JP et al., Vaccine 2020]
Regulatory Guidance for COVID-19 Vaccines

• Multivalent vaccines: ACCESS

  Multivalent

  ➢ Combination of a new sequence with the current sequence in the new vaccine version (i.e., generation of a bi- or multivalent vaccines) may necessitate additional immunogenicity studies to define the appropriate dose for each sequence and to investigate whether the addition of a second (or subsequent) sequence(s) does not result in an inferior immune response to vaccines with a single sequence. For example, competition at an mRNA level may occur and hamper immunogenicity.

  ➢ The reactogenicity of the combination should be evaluated, for example in comparison to the single sequence vaccine.

• Conventional placebo-controlled VE trial: What would be the primary endpoint?

• Immunologic non-inferiority of vaccine adapted to variant strain → ‘prototype’ vaccine in seronegatives

  ➢ FDA: seroresponse rate (NI margin 10%) and GMTs (1.5-fold)

  ➢ EMA: seroconversion rate = 4-fold increase with nominal value applied to pre-vaccination titre (NI margin 10%)

  ➢ WHO: endpoint not specified – seroconversion? (NI margin 10%) and GMT (LB 95% CI 0.67)
Developing Multivalent Vaccines: 3 Case Studies

- strain-specific immune response → may require imbalanced antigen concentration
- Immunodominance / immunotolerance
- Original antigenic sin
- Safety

<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Developers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takeda bivalent norovirus vaccine</td>
<td>Jim Sherwood, Takeda</td>
</tr>
<tr>
<td>Sanofi TIV to QIV influenza vaccine</td>
<td>Kevin Yin and Sandrine Samson, Sanofi</td>
</tr>
<tr>
<td>Moderna COVID-19 vaccines</td>
<td>Darin Edwards, Brett Leav, and Carla Vinals, Moderna</td>
</tr>
</tbody>
</table>
Multivalent vaccines
- Immunological considerations

Pr. Arnaud Didierlaurent
Center of Vaccinology, Geneva

Workshop: Multivalent COVID-19 vaccines to help address emergence of variants: CMC and Clinical implications

April 14th 2021
Questions

• Potential immunological mechanisms of interference/immunodominance in multivalent COVID-19 vaccines

• Possible mitigations and implications for clinical study design
In an ideal world... no immune interference

A + B versus A alone vs. B alone

Similar level of neutralizing antibody to A and B

Induction of a diverse cross-reactive memory B cell pool (grey: specific to conserved regions)
### Scenario 1: in naïve setting (neither previously infected, nor vaccinated)

<table>
<thead>
<tr>
<th>Potential interference mechanism</th>
<th>Expected Outcome</th>
<th>Possible mitigation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Competition for APC (B&gt;A)</strong></td>
<td>A + B</td>
<td>Assess different ratio of antigens in clinical studies</td>
</tr>
<tr>
<td><strong>Immunodominance (B&gt;A)</strong></td>
<td>Reduced response to A-specific neutralizing epitopes</td>
<td>Caveats for RNA/DNA/vector: limited by max. dose or risk of excessive reactogenicity?</td>
</tr>
</tbody>
</table>

Affinity to specific epitopes in B is higher than those in A.

Memory B cells biased towards B-specific epitopes.

Expected Outcome:
- Reduced response to A-specific neutralizing epitopes
- Memory B cells biased towards B-specific epitopes

Possible mitigation:
- Assess different ratio of antigens in clinical studies
- Caveats for RNA/DNA/vector: limited by max. dose or risk of excessive reactogenicity?
- Advantages for adjuvanted vaccines: possible to change Ag quantity while keeping Adjuvant dose constant
Scenario 2: in previously infected or vaccinated individuals (1/2)

Presence of A-specific Ab and memory B cells

Potential interference mechanism

Original Antigenic Sin
A-specific memory B cell preferentially stimulated over naïve B cell specific to variant B

Pre-existing Abs & memory B cells Specific to A

A-specific memory cell cross-reactive to new B epitope

Expected Outcome

Stimulation of cross-reactive memory B cells

A + B

A

B

neutralization

neutralization

The effect is amplified by the presence of the “ancestral” sequence in the multivalent vaccine

Possible mitigation

Risk of occurrence is reduced if initial vaccination/infection induces broad cross-reactive memory B cells

Use of “ancestral” sequence in multivalent vaccine to be avoided?
Scenario 2: in previously infected or vaccinated individuals (2/2)

Presence of A-specific Ab and memory B cells

Potential interference mechanism

Blunting by antibody

Direct Inhibition of B cell

Expected Outcome

Possible mitigation

**Potential interference mechanism**

**Blunting by antibody**

- Pre-existing Abs & memory B cells
- Naïve B cells

**Direct Inhibition of B cell**

- A alone
- B alone

**Expected Outcome**

- A + B

**Possible mitigation**

- Allow sufficient time after vaccination/infection
- Increase antigen dose to overcome blunting effect of pre-existing antibodies?

General blunting of the response but stronger effect on variant B (reduced stimulation of naïve B cells)
Key points

✓ Potential interference/immunodominance within antigens of multivalent vaccines is plausible, i.e. risk of original antigenic sin in those previously infected/vaccinated -> to be considered when deciding on or designing multivalent vaccine

✓ Antigen design and choice of vaccine platform may mitigate this risk

  ➢ Rational antigen design to favor cross-reactive Ab response (ex: Muecksch et al, 2021)

  ➢ Choose a different vaccine platform for booster (TRUE heterologous prime/boost)-> improve “fitness” of memory B cells

✓ “More is not always better”! – risk of “immunological overload”
Implications for study design/read-outs

✓ Assess potential increased reactogenicity in primed individuals (previously infected or vaccinated) if 2 doses are needed.

✓ Important to compare monovalent versus multivalent

✓ Critical to assess primed individuals in clinical studies as response in naïve individuals may not be representative
  ➢ Consider “worst-case scenario”, ie previously infected with original variant and vaccinated (2 doses)
  ➢ Consider adding a group with confirmed infection with different variants

✓ Key to have validated and standardized antibody cross-neutralization test to assess of established strains
Reasons to believe...

- Quality of antibodies (Breadth, potential for cross-neutralization) increases with time -> boosting several month after first vaccine/infection is beneficial\(^1,2\)

- In contrast to neutralizing antibodies, T cell responses in convalescent or vaccinated individuals are not substantially affected by variant mutations\(^3,4\) -> can support affinity maturation and improve B cell fitness

- Emerging evidence that previous infection with some variants elicited “fitter B cells” that may be recalled by vaccination

Recall of variant specific memory by vaccination with a different variant strain

A single mRNA vaccine dose boosts cross-variant neutralizing antibodies elicited by a previous infection with variants

Stamatatos et al. https://doi.org/10.1101/2021.02.05.21251182
Some variants may be better than other at inducing cross-protective response

Would an adapted vaccine based on this variant do the same?

Moyo-Gwete et al. https://www.medrxiv.org/content/10.1101/2021.03.06.434193; also reported by Cele et al; https://doi.org/10.1101/2021.01.26.21250224;
Thank you
Lessons learned in the development of multivalent bi-component Norovirus vaccine

COVAX Workshop 14 April 2021

Jim Sherwood, Scientific Director, Norovirus Vaccine Program
Takeda Global Vaccine Business Unit
Disclaimers

The information contained in this presentation is intended for use at this COVAX Workshop only.

TAK-214 has not been approved for use in indications under investigation in some of the trials or studies discussed herein and there is no guarantee it will be approved for such use.
Overview

- What is norovirus
- Disease and epidemiology
- Takeda’s norovirus vaccine candidate, TAK-214
- Lesson 1: genetic diversity and choice of antigens
cross-reactivity/protection
competition / interference between antigens
- Lesson 2: assessment of immunogenicity, assay development
immunobridging
- Lesson 3: selection of endpoints in efficacy trials
Norovirus structural characteristics

- Noroviruses are small, non-enveloped, icosahedral viruses, in the family Caliciviridae.
- 180 molecules of the norovirus capsid protein (VP1) are arranged as dimers, each divided into:
  - Shell (S) domain: Remains relatively conserved
  - Surface-exposed protruding (P) domain: Variability results in strain designation

ORF, open reading frame

Norovirus genotypes – 2015 vs 2019

Based on capsid sequences alone:
- 7 genogroups (2 infecting humans)
- 39 genotypes

Update classification system based on capsid as well as polymerase sequences. For capsid sequences:
- 10 genogroups + 2 tentative genogroups
- 49 genotypes + 5 tentative genotypes
For polymerase sequences:
- 8 P-groups + 2 tentative groups
- 60 P-types + 16 tentative P-types

Norovirus is highly infectious and responsible for widespread human disease\textsuperscript{1}:

Globally:

699 million cases and 200,000 deaths annually\textsuperscript{2}

Lesson 1 – selection of antigens and formulation

Factors considered in developing TAK-214

• Epidemiology
  – Include representative genotypes from the two genogroups that infect humans (at the time the vaccine was designed)
  – Strain variation
  – Incidence of different genotypes/strains by age group
• Cross reactivity (serological)- may or may not indicate cross protection
• Possible interference / competition of antigens (only considered later in the program)
• Selection of dose and regimen; may be different for other age groups (older adults, children)
Takeda’s Bivalent Norovirus vaccine candidate: TAK-214

**Virus-Like Particles Antigens (VLPs)**

- **GI.1**
  - Broadly cross-reacts with other GI strains

- **GII.4c**
  - Natural choice due to worldwide predominance of GII.4 strains

**Consensus Strategy**

- Presents epitopes from three different norovirus GII.4 strains on one VLP

**Adjuvant**

- **Aluminium Hydroxide**
  - Included in vaccine
  - To enhance immunogenicity

**Presentation**

- Prefilled Syringe (i.m.)
Emergent strains; importance of surveillance over time

- Noroviruses undergo genetic evolution through both antigenic drift and shift, and new genotypes and subtypes emerge approximately every 3 years\(^1\)
- GII.4 is the dominant genotype globally\(^2\) and caused all major norovirus epidemics in the last decade\(^3\)
- Emergent GII.4 strains rapidly replace existing strains and can cause seasons with unusually high norovirus activity\(^4\)\(^-\)\(^9\)
- A novel GII.17 variant was the dominant norovirus strain in Asia in 2014–2015, and was associated with an increase in AGE outbreaks\(^10\). This variant was present in the US at the beginning of the 2014–2015 season, suggesting that GII.17 may have the potential to become a new strain of global importance\(^11\)

Optimization of antigen formulations – NOR-107

A safety and immunogenicity study of various vaccine formulations in healthy adults
- Modified factorial design
- Compared different combinations of antigen, MPL, Alum and 1 vs 2 doses in two age groups

Results
- An imbalanced formulation with GII.4 > GI.1 provided the best response for GII.4
- In primed healthy adults, neither MPL nor a second dose conferred any additional immunological benefit that we were able to measure (Ab titres, persistence, CMI)

Caveat
- All subjects had been exposed to norovirus prior to entry

Leroux-Roles, J Infect Dis, 2018
Lesson 2 – assessment of immunogenicity – choice of assays

- Until 2019 norovirus were non-cultivable and a neutralization assay using this system is still under development\(^1\)
- A correlate of protection has been proposed but has yet to be confirmed\(^2\)
- Early trials explored binding Immunoglobins (serum IgG, IgA and a pan-Ig assay and salivary IgA)\(^2,3\)
- Noroviruses bind to human cells through attachment with histo-blood group antigens (HBGA) and a blocking assay for this binding has been developed\(^2\)
- Takeda is currently in the process of validating an HBGA blocking assay for use in late phase 2 and phase 3 development even though this is not a direct measurement of neutralization

Lesson 3 – selection of endpoints in efficacy trials

- Adult norovirus disease is outbreak driven – there are challenges in selecting the right population as well as the right efficacy endpoint.
- With outbreak driven disease there will always be an element of chance
- We used a “standard approach” to assess efficacy against vaccines components
- We considered other options:
  - “all noro” as primary endpoint
  - Co-primary endpoints
- Co infections? We chose to exclude endpoints with a co-pathogen in the protocol
- What about cross-protection? We included efficacy against non-vaccine genotypes as an exploratory endpoint.

- The NOR-211 story
NOR-211 Trial Design

- This was a double-blind, randomized, placebo-controlled study (NCT 02669121) to assess the efficacy of TAK-214 against norovirus associated acute gastroenteritis (AGE) in adults.
  - Primary objective was vaccine efficacy against moderate to severe norovirus AGE due to genotypes contained in the vaccine (GI.1/GII.4)
  - Secondary objective was vaccine efficacy against moderate to severe norovirus AGE due to any genotype
- The design was case driven with 30 primary endpoints required to provide 80% statistical power to reject the null hypothesis; primary objective would be considered met if the lower bound of the 95% CI was >0.
- Performed over two (winter) seasons: 2016-17 and 2017-18.
  - Location was US Navy Recruit Training Command, Great Lakes, IL, USA.
  - Participants were 18–49 year-old recruits randomized to two groups to receive:
    - one intramuscular dose of TAK-214 (n = 2,355) or saline placebo (n = 2,357)
## NOR-211 Efficacy outcomes – Norovirus AGE cases

<table>
<thead>
<tr>
<th>Identified Norovirus genotypes (all AGE severities)</th>
<th>Placebo (N=2377)</th>
<th>TAK-214 (N= 2371)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI.1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>G1.7a</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>GII.2</strong></td>
<td><strong>24</strong></td>
<td><strong>15</strong></td>
</tr>
<tr>
<td>GII.4</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td><strong>AGE severity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did not meet mild definition</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Mild</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Moderate</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>Severe</td>
<td>17</td>
<td>8</td>
</tr>
<tr>
<td><strong>Cases meeting Primary endpoint definition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine norovirus strains</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td><strong>Cases meeting Secondary endpoint definition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All norovirus strains</td>
<td>26</td>
<td>10</td>
</tr>
</tbody>
</table>

No cases of co-infection with *Salmonella, Shigella* or *Campylobacter* occurred.
NOR-211 Efficacy outcomes

• Based on the observed epidemiology we amended the SAP to allocate alpha error and allow analysis of the secondary endpoints

  - Primary endpoint = prevention of moderate/severe AGE due to vaccine genotypes of norovirus was based on 5 cases in placebo arm, 1 in TAK-214 arm (all GII.4).
    - Vaccine efficacy (VE) of 80.0% (99.99% CI, -1318.1 to 99.7; p = 0.142)
    - Lower bound of the 99.99% CI for VE was below 0% so primary objective was not met

• Secondary endpoint = prevention of moderate/severe AGE due to any genotype of norovirus was based on 26 cases (21 GII.2 and 5 GII.4) in placebo arm, 10 (9 GII.2 and 1 GII.4) in TAK-214 arm.
  - Vaccine efficacy (VE) of 61.8% (95.01% CI, 20.8 to 81.6; p = 0.0097)

• Ad hoc analysis = prevention of moderate/severe AGE due to GII.2 genotype of norovirus was based on 30 cases, 21 in the placebo arm and 9 in the TAK-214 arm
  - Vaccine efficacy (VE) of 57.4% (95% CI, 7.0 to 80.5; p=0.0321)
Thank You
High dose influenza vaccine: trivalent to quadrivalent

Kevin Yin, Global Medical Product Lead
Outline

• Emergence of influenza strains & vaccines valency

• Licensure of influenza vaccines & antibody response

• High dose (HD) influenza vaccine
  • Registration of HD trivalent vaccine
  • Immunobridging approach to license HD quadrivalent vaccine
Valency increase for influenza vaccines is not new

• Influenza strains emerge over time \(\rightarrow\) ↑ valency in vaccines

Circulating strains since 1938

Standard dose vaccines (unadjuvanted; for all ages)

- Monovalent → quadrivalent

IIV-HD vaccine (for 65+)

- Trivalent from 2009
- Quadrivalent from 2019

For COVAX Workshop Only; Not for further distribution
MAT-GLB-2101456/MAT-AU-2100830
Influenza vaccines: licensure based on antibody response

- Antibody level measured by haemagglutinin inhibition (HI) assay
- HI titre (e.g. seroconversion\(^*\)) = ‘proxy’ correlate of protection
- Efficacy trials important to confirm protection & necessary to claim superiority\(^1\)

\* A predefined increase in serum antibody concentration or titre

HD: a newer influenza vaccines for adults 65+

- 4x the antigen of standard dose unadjuvanted vaccine (IIV3-SD)
- Licensure of IIV3-HD

Phase III trial (2006-07)\(^1\)
- Superior antibody response over standard of care (IIV3-SD)

Accelerated licensure by FDA (2009)
- Commitment to post-licensure efficacy study

Post-licensure efficacy trial (2011-13)\(^2\)
- Superior efficacy over standard of care (IIV3-SD)


Abbreviations: IIV3-HD=high dose trivalent influenza vaccine; FDA=US Food and Drug Administration; IIV3-SD=standard dose, unadjuvanted trivalent influenza vaccine

For COVAX Workshop Only; Not for further distribution
MAT-GLB-2101456/MAT-AU-2100830
IIV3-HD: superior* antibody response over IIV3-SD

- Phase III RCT with 3,851 Americans 65+ in 2006-07
- Superior antibody response for 2 of 3 strains

![Bar chart showing GMT for A (H1N1) and B strains](chart)

- Acceptable reactogenicity

* Superiority was achieved if the lower bond of 95% confidence interval for the difference in seroconversion rates was >10%


Abbreviations: GMT=geometric mean titre; IIV3-HD=high dose trivalent influenza vaccine; RCT=randomised controlled trial; IIV3-SD=standard dose, unadjuvanted trivalent influenza vaccine

For COVAX Workshop Only; Not for further distribution. MAT-GLB-2101456/MAT-AU-2100830
IIV3-HD induced superior* efficacy over IIV3-SD

- Phase IV RCT with 31,989 Americans 65+ in 2011-12 & 2012-13

**Results**
- Superior efficacy against lab-confirmed influenza: 24%
- ↓ risk of serious events in IIV3-HD arm
- No safety concern identified

* As agreed with FDA, superiority was achieved if the lower bond of 95% confidence interval exceeded 9.1%


**Abbreviations:** IIV3-HD=high dose trivalent influenza vaccine; RCT=randomised controlled trial; IIV3-SD=standard dose, unadjuvanted trivalent influenza vaccine
IIV3-HD → IIV4-HD: immunobridging study

- **Based on demonstration of the non-inferior immunogenicity of IIV4-HD versus IIV3-HD, efficacy/effectiveness data of IIV3-HD to be inferred to IIV4-HD**
- **This approach recognised authorities; IIV4-HD now licensed in FDA, Europe & 4 other countries**

**Pivotal, superiority trial**

**Supportive, real world studies**

---

**Abbreviations:** IIV3-HD=high dose trivalent influenza vaccine; IIV3-SD=standard dose, unadjuvanted trivalent influenza vaccine; IIV4-HD=high dose quadrivalent influenza vaccine
Immunobridging RCT of IIV4-HD

HD Quadrivalent Influenza Vaccine
- Both B Lineages
- HDQIV
  - HDQIV
  - HD TIV-1

HD Trivalent Influenza Vaccine
- Victoria B Lineage
- HD TIV-1

HD Trivalent Influenza Vaccine
- Yamagata B Lineage
- HD TIV-2

2,670 Adults 65+

Primary and Secondary Objectives

1. **Non-inferior Immunogenicity (HAI assay)**
   - geometric mean titer ratios and seroconversion rates

2. **Superior Immunogenicity (HAI assay)**
   - of HD QIV versus the HD TIV which does not contain the corresponding B strain

3. **Assessment of Safety**
   - similar safety profile of HV QIV-HD versus TIV-HD

All were met (geometric mean titre results next slide)

*Note: As agreed with FDA, non-inferiority criteria used margins of 1.5 for GMTs and 10% for seroconversion rates; superiority was demonstrated if 95% CI for the difference of the log10 (GMT) for IIV4-HD vs. SD QIV was >log10 (1.5) and for the difference of seroconversion rates was >10%.

*Reference: Chang et al. Vaccine 2019; 37: 5825-34*
IIV4-HD induced non-inferior geometric mean titre (GMT) for all 4 strains vs. IIV3-HD

GMT, by study arm & strain*

<table>
<thead>
<tr>
<th>Strain</th>
<th>A/H1N1</th>
<th>A/H3N2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio of GMT</td>
<td>0.83</td>
<td>0.95</td>
</tr>
<tr>
<td>Lower bound of the CI*</td>
<td>0.742</td>
<td>0.841</td>
</tr>
</tbody>
</table>

Notes
* For simplification purpose, results for B lineages are not included in graph (available in publication by Chang et al.)
† Lower bound of the confidence interval (CI) should be >0.667 for non-inferiority to be reached


Abbreviations: CI=confidence interval; IIV4-HD=high dose quadrivalent influenza vaccine; IIV3-HD=high dose trivalent influenza vaccine
Key learnings: IIV3-HD → IIV4-HD

Influenza vaccines

↑ valency with emergence of new strains

Path to licensure: comparing with standard of care

IIV3-HD

↑ antibody response → accelerated licensure → post-licensure efficacy trial

Early access to better vaccine is important

IIV4-HD licensed via immunobridging approach

No additional efficacy trial required (given the proven clinical benefits of IIV3-HD)
Multivalent Variant mRNA COVID Vaccines

COVAX April 14 2021

Brett Leav, Darin Edwards
### Overview of Multi-Component Products

- **Vaccine with multiple antigens targeting the same pathogen**
- **Vaccine targeting multiple strains of the same pathogen**
- **Vaccine targeting multiple pathogens, i.e. similar antigens from different pathogens**
- **Therapeutics**

### Development Projects

- **CMV (mRNA-1647) pentamer complex subunits and gB** - 6x mRNAs in single vaccine - preclinical data showing no interference
- **Covid vaccine (flu model): 2x mRNAs in single vaccine**
- **HMPV/PIV (mRNA-1653)** - clinical data in S+ showed robust responses against each antigen
- **Cancer treatment, rare disease, etc.: Multiple mRNAs in single treatment Ex: Triplet for Oncology, OX40L, IL-23, and IL-36γ (mRNA-2752)**
Advancing a B.1.351-matched variant as a booster vaccine

Current State

- Sera from vaccinated NHPs/humans is routinely tested for ability to neutralize emerging variants of interest or concern
- B.1.351 strain first to show 5-10x reduction in neutralization (bottom, varies with sera and assay)

Implications for Moderna

- Prior to emergence of VOCs, mRNA-1273 CDP was testing a third vaccination of mRNA-1273, should annual boosters be required to maintain protective titers
- Moderna also now advancing strain-matched vaccine for boost and prime against VOCs
  - mRNA-1273.351 encodes for the full-length S-2P of B.1.351
  - mRNA-1273.211 is contains both mRNAs of mRNA-1273 and mRNA-1273.351, co-formulated into a single product
- As new strains emerge, the composition of the multivalent vaccine can evolve, like flu

Source: Kai Wu et al., “mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants”, Moderna & National Institutes of Health, National Institute of Allergy and Infectious Diseases
Vision for variant vaccine is a multivalent, boost indication for all comers

**Vision for Variant Vaccine**

- Vaccinated & Not previously infected subjects
- Vaccinated & Previously infected subjects
- Not vaccinated & Previously infected subjects

**Rationale**

- Closes an immunological gap that may lead to reduced efficacy of prototype vaccines
- Addresses epidemiology in different geographies
- Stepping stone to a multivalent primary series vaccine for all, resilient to continued evolution
- Experience with multi-component mRNA vaccines to date shows no interference
Planned Non-clinical Studies

1. Murine Studies
   - To confirm immunogenicity of primary series of modified vaccines in vivo and ability to boost immunity conferred by mRNA-1273 primary series
   - Sera tested for ability to neutralize a pseudovirion containing the B.1.351 spike protein (PsVNA-351), the spike protein of the Washington (PsVNA-WA) isolate + D614G, and other key variants of concern (P.1)

2. Hamster Studies
   - To assess cross protection (in late February / early March)
   - Determine if antibodies titers induced by mRNA-1273 are sufficient to protect against B.1.351
   - Test whether a third strain-matched vaccination improves protection
   - Understand if a multivalent prime and/or boost induces broad, cross-protective antibodies without interference

3. Non-Human Primates Studies
   - To confirm cross protection in a disease model highly relevant to correlates of protection
   - Determine if mRNA-1273 is sufficiently protective or if a strain-match vaccine is required to maintain vaccine efficacy.
Neutralizing Antibodies Elicited by mRNA-1273, mRNA-1273.351 or mRNA-1273.211 2 weeks after 2nd dose in Naïve Mice

1. Heterologous PsVN titers were lower for both mRNA-1273 and mRNA-1273.351 dosed animals
2. Multivalent mRNA-1273.211 produced similar neutralization titers against both viruses
3. A multivalent approach appears most effective in broadening immune response as a primary vaccination series

Source: Kai Wu et al., "Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice", bioRxiv Moderna & National Institutes of Health, National Institute of Allergy and Infectious Diseases
mRNA-1273.351 is an effective 3rd dose booster

1. Neutralizing titers increased against both B.1.351 and wild-type virus
2. Peak titers for both were well above the previous peak against the wild-type virus (2 weeks post dose 2)
3. Fold difference in two assays dropped from 6.6-fold before boost to 2-fold after 3rd dose
4. Ongoing in mice, hamsters, and NHP to evaluate boosting with monovalent mRNA-1273 or mRNA-1273.351 and multivalent mRNA.1273.211

Source: Kai Wu et al., "Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice", bioRxiv Moderna & National Institutes of Health, National Institute of Allergy and Infectious Diseases
### Variant Clinical Data Package

#### Phase 1 Variant Boost and Variant Primary study

<table>
<thead>
<tr>
<th>Primary Series Dose #1</th>
<th>Primary Series Dose #2</th>
<th>Boost</th>
</tr>
</thead>
<tbody>
<tr>
<td>1273</td>
<td>1273</td>
<td>.351</td>
</tr>
<tr>
<td>1273</td>
<td>1273</td>
<td>.211</td>
</tr>
<tr>
<td>.351</td>
<td>.351</td>
<td></td>
</tr>
<tr>
<td>1273</td>
<td>.351</td>
<td></td>
</tr>
<tr>
<td>.211</td>
<td>.211</td>
<td></td>
</tr>
</tbody>
</table>

- **Study Design:**
  - Booster dose in recipients of 1273 from Phase 1
  - Primary series in .351, 1273/.351 and .211
- **Endpoints:** Immunogenicity and safety
- N~20 per group

#### Phase 2 Variant Boost Study: Previously vaccinated participants

- **Study Design:** Booster dose in recipients of 1273 from Phase 3 to inform sample size
- **Endpoints:** Immunogenicity of .351 and .211
- N~20 per group

<table>
<thead>
<tr>
<th>Primary Series Dose #1</th>
<th>Primary Series Dose #2</th>
<th>Boost</th>
</tr>
</thead>
<tbody>
<tr>
<td>1273</td>
<td>1273</td>
<td>.351</td>
</tr>
<tr>
<td>1273</td>
<td>1273</td>
<td>.211</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary Series Dose #1</th>
<th>Primary Series Dose #2</th>
<th>Boost</th>
</tr>
</thead>
<tbody>
<tr>
<td>1273</td>
<td>.351</td>
<td></td>
</tr>
<tr>
<td>1273</td>
<td>.211</td>
<td></td>
</tr>
</tbody>
</table>

#### Phase 2 Variant Boost Study: Previously vaccinated participants

- **Study Design:** Booster dose in recipients of 1273 with sample size of TBD
- **Endpoints:** Immunogenicity and safety of .211
- N~300-500
Immunobridging Principles - Guidance Summary

**Population** | **Primary** | **Boost** | **Success criteria**
---|---|---|---
Naive | Prototype x 2 | Variant x 2 | \[
\frac{\text{GMT}_{\text{Variant}^1}}{\text{GMT}_{\text{Prototype}^2}} > 0.67
\]
\[
\frac{\text{GMT}_{\text{Prototype}^2}}{\text{GMT}_{\text{Variant}^1}} > 0.67
\]
\[
\text{GMT}_{\text{Variant}^*} > 1.0
\]
\[
\text{SR}_{\text{Variant}^1} - \text{SR}_{\text{Prototype}^2} \geq -10\%
\]

Prototype vaccinated | Prototype x 1 | Variant x 1 |

**Secondary endpoints**

Legend:
- SR = Seroresponse
- GMT: geometric mean titer

Note: ^1Modified vaccine against variant strain; ^2Prototype vaccine against original virus; ^*Strain used in assay
Immunobridging - Key Considerations

<table>
<thead>
<tr>
<th>Population</th>
<th>Primary</th>
<th>Boost</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naive</td>
<td>Prototype x 2</td>
<td>Variant x 2</td>
<td>• Binding/neutralizing assays against parent strain and variant strain are different</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Comparison of surrogate endpoints across strains of varying morbidity and mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Differences in absolute levels of neutralizing antibodies after primary course/pre-boost depending on vaccine manufacturer - comparison of post-boost titers to post-primary series titers does not allow for harmonization</td>
</tr>
<tr>
<td>Prototype vaccinated</td>
<td>Prototype x 1</td>
<td>Variant x 1</td>
<td>=&gt; Setting criteria for booster indication based on the immune response to a booster dose of vaccine in naturally infected subjects, or defining a fold increase vs baseline (ie &gt;2-fold) would allow for harmonization and booster indication for all-comers with history of vaccination or infection (eg pertussis booster)</td>
</tr>
</tbody>
</table>
## Multivalent Vaccines - Challenges and Opportunities

<table>
<thead>
<tr>
<th>Population</th>
<th>Primary</th>
<th>Boost</th>
<th>Challenges</th>
<th>Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naive</td>
<td>Prototype x 2</td>
<td>Multivalent x 2</td>
<td>• Potential for interference, complicated assessment of vaccine response</td>
<td>• Potential for synergy/cross-protection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Defining variants of concern/consequence for inclusion in vaccine - is there a limit to the number of variants in a multivalent vaccine?</td>
<td>• Lack of interference supported by non-clinical data</td>
</tr>
<tr>
<td>Prototype vaccinated</td>
<td>Prototype x 1</td>
<td>Multivalent x 1</td>
<td></td>
<td>• Providing broad coverage against prototype and variant for naive recipients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Establish platform to address co-circulating variants of concern/consequence</td>
</tr>
</tbody>
</table>
Thank You & Q&A
WHO support to regulatory preparedness

COVAX Workshop
Multivalent COVID-19 vaccines to help address emergence of variants: CMC and Clinical implications
14 April 2021

David Wood / Regulation and Prequalification, WHO
WHO is developing an integrated approach to monitoring/assessing SARS-CoV-2 variants.
Regulators have already developed national or regional guidance on evaluation of changes, if needed, to COVID-19 vaccines with established vaccine efficacy

- US FDA, EMA, ACCESS consortium (Australia, Canada, Singapore, Switzerland, UK) have guidance

For pandemic control, need a global approach

- WHO published guidance for PQ/EUL assessments
  - WHO will support mechanisms to foster global convergence

Speed is critical for developers

- Need to accelerate evidence generation for existing, modified, new vaccines
  - Rapid assessment and declaration of a VOC will accelerate the development process

Need rapid development of global standards
For candidate vaccines that are still in development additional guidance is required

- WHO will modify its Target Product Profile based on global public health considerations to guide what is needed
- ACCESS and EMA guidelines already provide some guidance for multivalent COVID vaccines
- Regulators have recognized the need that additional regulatory guidance is required for candidate vaccines that are still in development and are actively working on guidance for new vaccines
Clinical issues

• Risk of immunological interference. Need to demonstrate the immunological response to the first antigen is undeterred by the addition of the additional type(s).
• How to benchmark the response to the new antigen against the response of the prototype vaccine antigen.
• Safety: the impact of potentially increased antigen amount versus the risk of reduced-dosing failing non-inferiority.

CMC issues

Impact of multivalent formulations on potency assays and setting release specifications

Impact on formulation and stability

The difference between multiple DS that are blended together and multiple antigens in a single DS
Also need to consider possible scenarios for clinical studies for candidate vaccines that are still in development

<table>
<thead>
<tr>
<th>Placebo-controlled clinical efficacy studies are still possible</th>
</tr>
</thead>
<tbody>
<tr>
<td>If placebo-controlled trials are no longer feasible, study designs that enable randomization to be maintained and clinical outcomes to be maintained are possible</td>
</tr>
<tr>
<td>• Guidance needed on choice of comparator, endpoints, margins and minimum threshold for acceptability if non-inferiority designs used</td>
</tr>
<tr>
<td>Clinical immunobridging studies to generate reliable evidence for authorization could be used in some situations</td>
</tr>
<tr>
<td>• Guidance needed on immune markers predictive of protection</td>
</tr>
<tr>
<td>Potential role for human challenge studies</td>
</tr>
</tbody>
</table>
WHO support to regulatory preparedness

Global Standards

- Multiple written standards are available, including
  - TRS 1028, Annex 2, Guidelines on the quality, safety and efficacy of plasmid DNA vaccines
  - TRS 1011, Annex 2, Guidelines on Ebola vaccines
  - WHO guidance on mRNA vaccines for prevention of infectious diseases, in development
- Reference preparations
  - International Reference Panel and the first WHO International Antibody Standard for assay calibration

Naming of COVID-19 Vaccines

- International non-proprietary names (INN) have been assigned to mRNA-based COVID-19 vaccines and plasmid-based DNA COVID-19 vaccine candidates
- Accelerated process and nomenclature scheme for vaccines for variants to be announced
  - See INN Request form
WHO support to regulatory preparedness

• Prequalification and Emergency Use Listing procedure
  • WHO has placed into the public domain the status of COVID-19 vaccines for which an expression of interest has been received by WHO/PQ
    • Please visit the site regularly for the latest updated version.
  • Guidance for PQ/EUL assessments
• Regulatory support to countries
  • >100 countries supported to issue regulatory authorizations for vaccines supplied through the COVAX Facility
Key messages

- A globally coordinated response is essential for
  - identifying variants of concern,
  - their impact on vaccines, and
  - any modifications to vaccine composition

- Regulatory alignment to assess modifications to SARS CoV-2 vaccines with established efficacy is largely achieved – but detailed guidance on multivalent vaccines not yet provided

- Further regulatory guidance is being developed

- Careful messaging is essential so as not to disturb public trust in COVID-19 vaccines
Thank you all for your participation and engagement today.
Workshop report will be distributed shortly to summarize today’s conversation.
We will continue to share resources at the website here: https://epi.tghn.org/covax-overview/clinical-science/

**Other COVAX workshops:**
- April 16 COVAX Enabling Sciences Workshop: Global and local approaches to detect and interpret SARS-CoV-2 variants
- April 28 Vaccine Safety workshop: COVID 19 Vaccines Risk Management Planning: Stakeholders Experiences and Perspectives
- Mid-May (TBC) -- COVAX Clinical Development and Operations Workshop

The COVAX Manufacturing and Clinical SWAT Teams plan to continue sharing learnings across developers as we pursue our common goal – a global supply of safe and effective vaccines.
Thank you